EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women – Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled study

Tommaso Simoncini, Céline Bouchard, Marie Cloes, Mélanie Taziaux, Santiago Palacios, Sebastião Freitas de Medeiros, Valeriu Vrabii, David F Archer, Nick Panay

Maturitas · 2026

DOI: 10.1016/j.maturitas.2026.108965 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Maturitas, 2026. Verfasst von Tommaso Simoncini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Hot Flashes, Postmenopause, Estetrol, Vasomotor System. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gedeon Richter.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the efficacy and safety of estetrol in reducing moderate to severe vasomotor symptoms in postmenopausal women. METHODS: Multicenter, randomized, parallel group (1:1:1), placebo-controlled, double-blind, phase 3 study in hysterectomized and non-hysterectomized participants aged 40-65 years. A total of 640 participants with seven or more moderate to severe hot flashes daily or 50 weekly received estetrol 15 mg, estetrol 20 mg, or placebo for 12 weeks. Co-primary endpoints were the change in frequency and severity of moderate to severe vasomotor symptoms from baseline to weeks 4 and 12. Comparisons versus placebo were made using a mixed-effects model for repeated measures. The safety of estetrol alone was evaluated in relation to treatment-emergent adverse events. RESULTS: Estetrol 15 mg and 20 mg produced significant reductions in the weekly frequency of moderate to severe vasomotor symptoms at week 4 (least square means: -9.63, P = 0.038; and - 14.94, P < 0.001) and at week 12 (-16.41, P < 0.001; and - 22.49, P < 0.001), relative to placebo. Vasomotor symptom severity was significantly reduced with both estetrol doses at week 4 (-0.27, P = 0.011; and - 0.29, P = 0.005) and at week 12 (-0.54 and - 0.66 [both P < 0.0001]), compared with placebo. Drug-related treatment-emergent adverse events occurred in 51.6%, 57.3%, and 20.6% of participants in the estetrol 15 mg, 20 mg, and placebo groups, respectively, with discontinuations due to treatment-emergent adverse events in 6.6%, 7.5%, and 2.3%, respectively. CONCLUSIONS: Estetrol reduced the frequency and severity of moderate to severe vasomotor symptoms and was well tolerated, with low discontinuation rates, supporting its use in symptomatic postmenopausal women. CLINICAL TRIAL REGISTRATION: NCT04209543.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hot FlashesPostmenopauseEstetrolVasomotor SystemHumansFemaleDouble-Blind MethodMiddle AgedAdultAgedTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

E4EstetrolHormone therapyMenopauseVasomotor symptoms

Substanzen

Estetrol

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Clinique de Recherche en Santé des Femmes, Québec, Canada.
  • Estetra SRL, a wholly owned subsidiary of Gedeon Richter Plc., Liège, Belgium.
  • Estetra SRL, a wholly owned subsidiary of Gedeon Richter Plc., Liège, Belgium. Electronic address: taziauxm@gedeonrichter.com.
  • Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain.
  • Instituto Tropical de Medicina Reprodutiva - Clinica INTRO, Mato Grosso, Brazil.

Förderung

  • Gedeon Richter

Zitieren

APA

Simoncini, T., Bouchard, C., Cloes, M., Taziaux, M., Palacios, S., de Medeiros, S. F., Vrabii, V., Archer, D. F., & Panay, N. (2026). Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women – Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled study. Maturitas. https://doi.org/10.1016/j.maturitas.2026.108965

Vancouver

Simoncini T, Bouchard C, Cloes M, Taziaux M, Palacios S, de Medeiros SF, et al. Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women – Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled study. Maturitas. 2026. doi:10.1016/j.maturitas.2026.108965

BibTeX
@article{Simoncini2026,
  author = {Simoncini, Tommaso and Bouchard, Céline and Cloes, Marie and Taziaux, Mélanie and Palacios, Santiago and de Medeiros, Sebastião Freitas and Vrabii, Valeriu and Archer, David F and Panay, Nick},
  title = {Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women – Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled study},
  journal = {Maturitas},
  year = {2026},
  doi = {10.1016/j.maturitas.2026.108965}
}
Kostenlos starten →